Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 6
1981 8
1982 3
1983 7
1984 2
1985 8
1986 13
1987 13
1988 16
1989 9
1990 12
1991 17
1992 10
1993 9
1994 10
1995 6
1996 9
1997 8
1998 9
1999 15
2000 13
2001 12
2002 13
2003 13
2004 14
2005 6
2006 11
2007 14
2008 21
2009 14
2010 13
2011 18
2012 18
2013 19
2014 17
2015 9
2016 7
2017 7
2018 4
2019 2
2020 4
2021 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

430 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 diabetes in adolescents and young adults.
Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Lascar N, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2018 Jan;6(1):69-80. doi: 10.1016/S2213-8587(17)30186-9. Epub 2017 Aug 25. Lancet Diabetes Endocrinol. 2018. PMID: 28847479 Review.
Exenatide.
Barnett AH. Barnett AH. Drugs Today (Barc). 2005 Sep;41(9):563-78. doi: 10.1358/dot.2005.41.9.893704. Drugs Today (Barc). 2005. PMID: 16341288 Review.
Insulin analogues.
Barnett AH, Owens DR. Barnett AH, et al. Lancet. 1997 Jan 4;349(9044):47-51. doi: 10.1016/S0140-6736(96)06032-1. Lancet. 1997. PMID: 8988131 Review. No abstract available.
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Barnett AH, et al. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Lancet Diabetes Endocrinol. 2014. PMID: 24795251 Clinical Trial.
Insulin icodec: evolution or revolution in diabetes therapy?
Bellary S, Barnett AH. Bellary S, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2023 Jun;11(6):379-380. doi: 10.1016/S2213-8587(23)00125-0. Epub 2023 May 4. Lancet Diabetes Endocrinol. 2023. PMID: 37150185 No abstract available.
Ensemble Reweighting Using Cryo-EM Particle Images.
Tang WS, Silva-Sánchez D, Giraldo-Barreto J, Carpenter B, Hanson SM, Barnett AH, Thiede EH, Cossio P. Tang WS, et al. Among authors: barnett ah. J Phys Chem B. 2023 Jun 22;127(24):5410-5421. doi: 10.1021/acs.jpcb.3c01087. Epub 2023 Jun 9. J Phys Chem B. 2023. PMID: 37293763
Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V, Barnett AH. Jahagirdar V, et al. Among authors: barnett ah. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. Expert Opin Pharmacother. 2014. PMID: 25301180 Review.
Future glucose-lowering drugs for type 2 diabetes.
Bailey CJ, Tahrani AA, Barnett AH. Bailey CJ, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2016 Apr;4(4):350-9. doi: 10.1016/S2213-8587(15)00462-3. Epub 2016 Jan 23. Lancet Diabetes Endocrinol. 2016. PMID: 26809680 Review.
430 results